PALO ALTO, Calif., Feb. 4, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that senior management will present the Company's pipeline program exploring the treatment of glaucoma at the Glaucoma 360 New Horizons Forum 2025 on Friday, February 7, 2025, in San Francisco, CA. Glaucoma is the leading cause of irreversible blindnes ...

PALO ALTO, Calif., Jan. 7, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025, at 3:00 p.m. Pacific Time. A live webcast of the presentation will be available ...

Kodiak Sciences Stock Performance - Kodiak Sciences (KOD) shares have surged 270.7% in the past six months, driven by updates on its lead investigational candidate, tarcocimab [1] - Over the past year, KOD shares have risen 201%, outperforming the industry's 15.7% decline [5] Tarcocimab Development Program - Tarcocimab, a novel anti-VEGF antibody biopolymer conjugate, is being evaluated for retinal vascular diseases [1] - Following positive phase III results from the GLOW1 study, Kodiak rebooted tarcocimab's development program in late 2023 [2] - The GLOW2 study, initiated in late 2023, is enrolling patients and aims to support a biologics license application for diabetic retinopathy (DR) [2] - The revival of tarcocimab has restored stakeholder confidence in its potential for treating retinal diseases [3] Financial Analyst Outlook - Jefferies upgraded KOD to a "BUY" rating, citing a major "turnaround story" for 2025 [4] - Jefferies set a target price of $20 per share ($1 billion market cap) for 2025, projecting a potential rise to $30-$50 per share ($1.5-$3 billion market cap) by 2026 [4] KSI-501 Development - KSI-501, a dual inhibitor bioconjugate molecule, is being developed for retinal vascular diseases [7] - Following a successful phase I study, Kodiak is advancing KSI-501 into phase III through the DAYBREAK study for wet AMD [8] - The DAYBREAK study will also evaluate tarcocimab as a second investigational arm, positioning Kodiak with two late-stage candidates [8] KSI-101 Development - KSI-101, the unconjugated protein component of KSI-501, targets IL-6 and VEGF for diabetic macular edema (DME) and macular edema secondary to inflammation (MESI) [9] - The phase Ib APEX study is enrolling patients to evaluate KSI-101's safety and tolerability, with plans to progress into late-stage development [10] - Pivotal phase IIb/III studies (PEAK and PINNACLE) will investigate KSI-101 in MESI [10] Financial Position and Investor Interest - Kodiak ended Q3 with $197.9 million in cash, cash equivalents, and marketable securities, sufficient to support operations into 2026 [12] - The company is gaining significant interest from healthcare funds due to its attractive valuation and may seek financing in 2025 [11] Industry Comparison - Castle Biosciences (CSTL) shares have gained 59.4% in six months, with earnings beating estimates in the past four quarters [14] - Vanda Pharmaceuticals (VNDA) shares have lost 8% in six months, with a negative earnings surprise in the past four quarters [15] - CytomX Therapeutics (CTMX) shares have lost 13.1% in six months, with mixed earnings performance in the past four quarters [16][17]

Kodiak Sciences Inc. (KOD) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KOD's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross."There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. ...

Kodiak Sciences (KOD) incurred a loss of 84 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 90 cents. The company had incurred a loss of 95 cents per share in the year-ago quarter.The company currently does not have any approved products in its portfolio. As a result, it has yet to generate revenues.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.KOD’s Q3 Results in DetailResearch and development expenses were $31.9 million in the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 KODIAK SCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0476525 (S ...

Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results Palo Alto, CA — November 14, 2024 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Investor R&D Day webcast and presentation provide a comprehensive and up-to-date overview o ...

PALO ALTO, Calif., Nov. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024."In the third quarter we hosted an Investor R&D Day in New York," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Investor R&D Day webcast and presentation provide a comprehensive and up-to-date overview of where we stand today and where we are going – this is what I call 'Kodiak 2.0'. The video web ...

PALO ALTO, Calif., Nov. 11, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences. Members of the management team will also be available for one-on-one meetings. Jefferies London Healthcare Conference, November 21, 2024, 9:00 AM GMT (1:00 AM PT), London, UK ...

PALO ALTO, Calif., Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois. Presentation and Panel details are below: Presentation Title: Update on Antibody Biopolymer Conjugates: Optimizing Immediacy and Durabilit ...